Akero Therapeutics AKRO 深 滬
等待開盤 08-05 09:30:00 美东时间
48.62
+0.250
+0.52%
華盛通- 最 高49.92
- 今 開49.92
- 成交量 119.17万股
- 最 低 48.32
- 昨 收 48.37
- 總市值 38.76亿
- 52周最高 58.40
- 市盈率 靜 --
- 換手率 1.49%
- 52周最低 21.34
- 委 比 -41.27%
- 總股本 7971.76万
- 歷史最高 58.40
- 量 比 1.33
- 振 幅 3.31%
- 歷史最低 7.52
- 每 手 1
- 風險率 10.58%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多TD Cowen Initiates Coverage On Akero Therapeutics with Buy Rating, Announces Price Target of $76
TD Cowen analyst Ritu Baral initiates coverage on Akero Therapeutics (NASDAQ:AKRO) with a Buy rating and announces Price Target of $76.
08-04 19:38
恒申安科罗年产10万吨改性塑料项目动工
近日，恒申安科罗年产10万吨改性工程材料项目正式动工建设，一期产能为5万吨。据悉，该项目总投资10亿元，占地面积110亩，总建筑面积约15万平方米。企业规划建设...
07-22 18:12
Akero Therapeutics’ Efruxifermin Study: A Potential Game-Changer for NASH/MASH Treatment
Akero Therapeutics (($AKRO)) announced an update on their ongoing clinical stud...
06-27 00:23
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
Akero Therapeutics announced that its management will present at the Jefferies Global Healthcare Conference on June 4, 2025. The presentation will be webcast live and archived on the company's website. Akero develops treatments for serious metabolic diseases like metabolic dysfunction-associated steatohepatitis (MASH). Its lead candidate, efruxifermin (EFX), is in Phase 3 trials. The company is based in South San Francisco.
05-28 11:00
美股大行评级 | 潜在涨幅1562.13%！Cingulate获Ascendiant Capital升目标价至61美元，维持"买入"评级
潜在涨幅1562.13%！Cingulate获Ascendiant Capital升目标价至61美元，维持"买入"评级
05-28 09:04
B of A Securities Maintains Buy on Akero Therapeutics, Raises Price Target to $64
B of A Securities analyst Alexandria Hammond maintains Akero Therapeutics (NASDAQ:AKRO) with a Buy and raises the price target from $63 to $64.
05-27 23:20
美股牛股 | 月内累涨超640%！脑再生科技再涨27%；量子计算股QBTS升超25%
月内累涨超640%！脑再生科技再涨27%；QBTS发布新一代量子计算系统，股价飙升超25%>>
05-21 18:45
美股大行评级 | 潜在涨幅158.9%！蒙特利尔银行上调Disc Medicine目标价至120美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1129333511617925121.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 蒙特利尔银行：维持Disc Medicine(IRON)"跑赢大市"评级，目标价从112美元升至120美元</p> <p>• 巴克莱：维持Karyopharm Therapeutics(KPTI)"超配"评级，目标价从5美
05-14 08:48
Akero Therapeutics Q1 2025 EPS $(0.90) Beats $(0.99) Estimate, Cash, Cash Equivalents, And Short- And Long-term Marketable Securities As Of March 31, 2025, Were $1.128B, Will Be Sufficient To Fund Its Current Operating Plan Into 2028
Phase 2b SYMMETRY study preliminary results showed statistically significant reversal of compensated cirrhosis (F4) due to MASH following 96 weeks of treatment with efruxifermin (EFX)Presented two oral presentations and
05-12 19:20
